Elsevier

Neuroscience Letters

Volume 187, Issue 3, 10 March 1995, Pages 165-168
Neuroscience Letters

Ketobemidone, methadone and pethidine are non-competitive N-methyl-d-aspartate (NMDA) antagonists in the rat cortex and spinal cord

https://doi.org/10.1016/0304-3940(95)11364-3Get rights and content

Abstract

The opiate agonists, ketobemidone, methadone and pethidine, were evaluated as N-methyl-d-aspartate (NMDA) receptor antagonists using the rat cortical wedge preparation and the neonatal rat spinal cord preparation for electrophysiological studies and [3H](RS)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine ([3H]MK-801) binding experiments using rat forebrain homogenates. Ketobemidone, methadone and pethidine were inhibitors of [3H]MK-801 binding with Ki values of 26 μM, 0.85 μM and 47 μM, respectively. In the cortex, 1 mM ketobemidone and 1 mM methadone reduced NMDA responses, but not (RS)-2-amino-3-(3-hydroxy5-methylisoxazol-4-yl)propionic acid (AMPA) or kainate responses in an use-dependent manner, whereas 1 mM pethidine was devoid of antagonist activity. In the spinal cord preparation, the activities of ketobemidone and methadone were weaker than in cortex. In contrast, pethidine was equipotent with ketobemidone in the spinal cord. These results suggest that ketobemidone and methadone may be useful therapeutic agents in conditions where a combined opiate agonist and NMDA antagonist treatment is desired.

References (26)

  • C.B. Christensen

    The opioid receptor binding profiles of ketobemidone and morphine

    Pharmacol. Toxicol.

    (1993)
  • J. Glowinski et al.

    Regional studies of catecholamines in the rat brain. I. Disposition of 3H-norepinephrine, 3Hdopamine and 3H-dopa in various regions of the brain

    J. Neurochem.

    (1966)
  • J.T. Greenamyre et al.

    Glutamate transmission and toxicity in Alzheimer's disease

    Prog. Neuro-Psychopharmacol. Biol. Psychiatry

    (1988)
  • Cited by (224)

    • Anesthesia and analgesia in laboratory rodents

      2023, Anesthesia and Analgesia in Laboratory Animals
    • BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, produces potent antinociceptive effects with safer properties than morphine

      2020, Neuropharmacology
      Citation Excerpt :

      Thus, MOP-mediated β-arrestin recruitment may not be responsible for the side effects of BPR1M97, and the molecular mechanisms of BPR1M97 on gastrointestinal function should be evaluated by further research. Second, opioids such as morphine, naloxone, and methadone have been reported to activate nonopioid receptors, including the NMDA receptor (Ebert et al., 1995), TLR4 (Wang et al., 2012, 2016), and TREK-1 (Devilliers et al., 2013). Whether other nonopioid receptors are involved in BPR1M97 pharmacology should be determined.

    • 5.39 - Neuropathic Pain: Mechanisms, Clinical Aspects and Treatment Options

      2020, The Senses: A Comprehensive Reference: Volume 1-7, Second Edition
    View all citing articles on Scopus
    View full text